Trial Profile
Efficacy and Safety of LAIS Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy (Primary)
- Indications Allergic asthma; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- 22 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 31 Oct 2014 New trial record